2019
The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving
de Laat B, Goldberg A, Shi J, Tetrault JM, Nabulsi N, Zheng MQ, Najafzadeh S, Gao H, Kapinos M, Ropchan J, O'Malley SS, Huang Y, Morris ED, Krishnan-Sarin S. The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving. Biological Psychiatry 2019, 86: 864-871. PMID: 31399255, DOI: 10.1016/j.biopsych.2019.05.021.Peer-Reviewed Original ResearchConceptsKappa-opioid receptorsAlcohol use disorderOpioid receptorsUse disordersNonselective opioid receptor antagonistModest clinical effectsEfficacy of naltrexoneOpioid receptor antagonistDSM-IV criteriaPositron emission tomographyAlcohol Urge QuestionnaireNaltrexone initiationNaltrexone therapyClinical effectsReceptor antagonistTherapeutic effectCingulate cortexDrinking paradigmHeavy drinkersBilateral insulaNaltrexoneAlcohol dependenceBrain regionsEmission tomographyPrefrontal cortex
2018
Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users
Roberts W, Shi JM, Tetrault JM, McKee SA. Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users. Journal Of Addiction Medicine 2018, 12: 227-233. PMID: 29438157, PMCID: PMC5970035, DOI: 10.1097/adm.0000000000000392.Peer-Reviewed Original ResearchConceptsLow-dose naltrexoneTobacco usersTreatment outcomesPlacebo-controlled human laboratory studySmoking cessation treatmentEffects of vareniclineCigarettes ad libitumHuman laboratory studiesSubjective drug effectsVarenicline monotherapyCessation medicationsMedication therapyCessation treatmentMedication armTobacco useVareniclineLow doseSmoking relapseSmokingDrug effectsSmoking outcomesSmoking behaviorNaltrexoneCarbon monoxide levelsHeavy drinkers
2009
Varenicline Reduces Alcohol Self-Administration in Heavy-Drinking Smokers
McKee SA, Harrison EL, O'Malley SS, Krishnan-Sarin S, Shi J, Tetrault JM, Picciotto MR, Petrakis IL, Estevez N, Balchunas E. Varenicline Reduces Alcohol Self-Administration in Heavy-Drinking Smokers. Biological Psychiatry 2009, 66: 185-190. PMID: 19249750, PMCID: PMC2863311, DOI: 10.1016/j.biopsych.2009.01.029.Peer-Reviewed Original ResearchConceptsHeavy drinking smokersSelf-administration periodAlcohol consumptionPartial nicotinic agonistPlacebo-controlled investigationEffects of vareniclineReduced ethanol intakeAlcohol Self-AdministrationAlcohol use disorderNicotinic acetylcholine receptorsMedication pretreatmentAdverse eventsNumber of drinksPreclinical evidenceAdditional drinkEthanol intakeTobacco dependenceDaily smokersPriming doseVareniclineComorbid disordersNicotinic agonistsUse disordersPriming drinkPotential treatment
2007
Family History of Alcoholism Influences Naltrexone-Induced Reduction in Alcohol Drinking
Krishnan-Sarin S, Krystal JH, Shi J, Pittman B, O’Malley S. Family History of Alcoholism Influences Naltrexone-Induced Reduction in Alcohol Drinking. Biological Psychiatry 2007, 62: 694-697. PMID: 17336941, DOI: 10.1016/j.biopsych.2006.11.018.Peer-Reviewed Original ResearchConceptsAlcohol drinkingFamily historyDrinking periodDose of naltrexoneSignificant clinical predictorsNaltrexone therapyClinical predictorsNaltrexone dosePriming doseMale drinkersNaltrexoneAlcohol-dependent participantsSecondary analysisDoseAlcoholic drinksDrinkingAlcoholismDrinkersDrinksDaysTotal numberParticipantsTherapy